Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis to complete Zentiva acquisition

This article was originally published in Scrip

Executive Summary

Sanofi-Aventis will hold a 94% stake in the Czech Republic's Zentiva when it completes its acquisition on March 11th. All the conditions put out by Sanofi-Aventis Europe, a subsidiary which is handling the deal, have been successfully fulfilled, it added.

You may also be interested in...



Sanofi Finalizes Zentiva Sale With Focus Back On Turnaround

A share purchase agreement for the sale of Zentiva has been signed with private equity group Advent, so Sanofi can concentrate on making the most of its new acquisitions.

Poland's new law fixes prices and trade mark-ups of reimbursed drugs

Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.

Global pharma boosts business in Russia - Why Russia (introduction)

In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.

Topics

Related Companies

UsernamePublicRestriction

Register

SC000506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel